1. Home
  2. Sistema de Salut de Catalunya
  3. Vall d'Hebron Hospital Universitari – HVH
  4. Articles científics - HVH
  5. View Item

7317 CAHtalyst Pediatric: Results From The Randomized, Double-Blind, Placebo-Controlled Period Of A Phase 3 Trial Of Crinecerfont, A Corticotropin-Releasing Factor Type 1 Receptor Antagonist, In Children And Adolescents With Classic Congenital Adrenal Hyperplasia

To access the full text documents, please follow this link: https://hdl.handle.net/11351/12380

Author

Sarafoglou, Kyriakie

Kim, Mimi

Lodish, Maya

Felner, Eric

Martinerie, Laetitia

Nokoff, Natalie

Clemente, Maria

Other authors

Institut Català de la Salut

[Sarafoglou K] University of Minnesota Medical School and College of Pharmacy, Minneapolis, MN. [Kim MS] Children’s Hospital of Los Angeles, Los Angeles, CA. Keck School of Medicine of USC, Los Angeles, CA. [Lodish M] University of California San Francisco, Berkeley, CA. [Felner EI] Emory University School of Medicine, Atlanta, GA. Children’s Healthcare of Atlanta (CHOA), Atlanta, GA. [Martinerie L] Hôpital Universitaire Robert Debré, AP-HP, Université Paris Cité, Paris, France. [Nokoff NJ] University of Colorado Anschutz Medical Campus, Aurora, CO. [Clemente M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Instituto de Salud Carlos III, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2025-01-08T11:05:23Z

2025-01-08T11:05:23Z

2024-10-05



Share

Abstract

Corticotropin-releasing factor; Children; Classic congenital adrenal hyperplasia

Factor alliberador de corticotropina; Nens; Hiperplàsia suprarenal congènita clàssica

Factor liberador de corticotropina; Niños; Hiperplasia suprarrenal congénita clásica

Document Type

Article

Published version

Language

English

Subjects and keywords

Infants; Malalties congènites - Tractament; Hiperplàsia - Tractament; ACTH; NAMED GROUPS::Persons::Age Groups::Child; DISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Congenital Abnormalities::Urogenital Abnormalities::Disorders of Sex Development::Adrenogenital Syndrome::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Adrenal Hyperplasia, Congenital; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, G-Protein-Coupled::Receptors, Corticotropin-Releasing Hormone; DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño; ENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::anomalías congénitas::anomalías urogenitales::trastornos del desarrollo sexual::síndrome adrenogenital::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades y anomalías neonatales congénitas y hereditarias::hiperplasia suprarrenal congénita; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores acoplados a proteínas G::receptores de hormona liberadora de corticotropina

Publisher

Oxford University Press

Related items

Journal of the Endocrine Society;8(Supplement_1)

https://doi.org/10.1210/jendso/bvae163.127

Recommended citation

This citation was generated automatically.

Export

DIDL MARC MARC_CCUC METS OAI_DC ORE QDC RDF

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)

Articles científics - HVH [3440]